Net sales of insulin medications of Novo Nordisk in Greater China 2022, by type

In 2022, the Danish pharmaceutical company Novo Nordisk reported a net sales of over 4.9 billion Danish kroner from its premix insulin in Greater China. Diabetes care drug is the key product of the firm, generating over 15.2 billion net sales in the region that year.

2022年，丹麦制药公司诺和诺德（Novo Nordisk）从其在中国大陆的预混胰岛素产品中实现了超过49亿丹麦克朗的净销售额。糖尿病护理药物是该公司的核心产品，当年在该地区创造了超过152亿丹麦克朗的净销售额。